Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186344 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Jul, 2025
(2 years from now) | |
US8697748 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Oct, 2025
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 30, 2027 |
New Chemical Entity Exclusivity (NCE) | Jun 30, 2025 |
Drugs and Companies using TRIHEPTANOIN ingredient
NCE-1 date: 2024-06-30
Market Authorisation Date: 30 June, 2020
Treatment: NA
Dosage: LIQUID;ORAL
11
United States
3
Canada
2
Mexico
2
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic